MXCT - NASDAQ

MaxCyte, Inc.

MXCT·NASDAQ

$1.21

-0.22%

HealthcareMedical - Devices

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$129.08M

EPS-0.4200

P/E Ratio-2.87

Earnings Date08/12/2026

202.51M

Assets

-15%

3Y-29.0%

5Y+291.0%

10Y+1160.0%

31.02M

Total Liabilities

-7%

3Y-5.0%

5Y+67.0%

10Y+182.0%

171.49M

Total Equity

-17%

3Y-32.0%

5Y+416.0%

10Y+3274.0%

MaxCyte, Inc. Funding & Solvency Profile

MXCT · NASDAQ

Current Assets

Cash & Cash Equivalents20.07M

Net Receivables3.50M

Inventory7.55M

Other Current Assets4.28M

Total Current Assets118 M

Non-Current Assets

Property, Plant & Equipment28.45M

Goodwill & Intangible Assets650.00K

Long-Term Investments52.57M

Other Non-Current Assets2.47M

Total Non-Current Assets83 M

Total Assets

202.51M

Financial Health Analysis

Current Ratio

8.30x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.18x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

104 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

58% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

MaxCyte, Inc. Balance Sheet

MXCT • NASDAQ

MaxCyte, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	20.1M	27.9M	46.5M	11.1M	47.8M	18.8M	15.2M	11.2M	25.3M	11.7M	2.4M	3.4M	764.9K	1.4M
Short-Term Investments	83M	126.6M	121.8M	216.3M	207.3M	16M	1.5M	3.2M	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	103M	154.5M	168.3M	227.3M	255M	34.8M	16.7M	14.4M	25.3M	11.7M	2.4M	3.4M	764.9K	1.4M
Net Receivables	3.5M	4.7M	5.8M	11.2M	6.9M	5.2M	3.2M	4.9M	3.2M	2.4M	1.5M	1.4M	767.1K	621.7K
Accounts Receivables	3.5M	4.7M	5.8M	11.2M	6.9M	5.2M	3.2M	4.9M	3.2M	2.4M	1.5M	1.4M	767.1K	621.7K
Inventory	7.5M	8.9M	12.2M	8.6M	5.2M	4.3M	3.7M	2.2M	1.3M	1.3M	1.1M	941.1K	726.8K	514.9K
Prepaids	0.0	0.0	0.0	3.3M	3.3M	1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Assets	4.3M	3.6M	3.9M	1.9M	0.0	0.0	797.1K	863.7K	665.8K	318.4K	1.2M	276K	64.4K	51.2K
Total Current Assets	118.4M	171.7M	190.2M	252.3M	270.4M	45.3M	24.5M	22.5M	30.6M	15.8M	6.2M	6M	2.3M	2.6M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	28.5M	30.5M	34.8M	33.6M	13.4M	6.5M	5.5M	1.8M	847.6K	281.5K	207.3K	236.2K	181.2K	204K
Intangible Assets	650K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	650K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	52.6M	35.8M	42.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	2.5M	1.5M	388K	809K	316.7K	33.9K	-5.5M	0.0	0.0	0.0	0.0	37K	0.0	31.5K
Total Non-Current Assets	84.1M	67.8M	78.1M	34.4M	13.7M	6.5M	5.5M	1.8M	847.6K	281.5K	207.3K	273.2K	181.2K	235.5K
Total Assets	202.5M	239.5M	268.3M	286.7M	284.1M	51.8M	30M	24.3M	31.4M	16.1M	6.4M	6.3M	2.5M	2.8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.4M	1.4M	743K	292K	1.8M	890.2K	2.1M	1M	4.3M	3.2M	2.3M	1.4M	1.4M	1M
Accounts Payable	1.4M	1.4M	743K	292K	1.8M	890.2K	2.1M	1M	4.3M	3.2M	2.3M	1.4M	1.4M	1M
Accrued Expenses	0.0	0.0	11.3M	8.3M	6.5M	5.2M	3.6M	3.1M	0.0	0.0	0.0	0.0	0.0	0.0
Short Term Debt	1.5M	864K	0.0	0.0	0.0	0.0	0.0	0.0	850.9K	0.0	805.7K	1.4M	1.8M	1.8M
Capital Lease Obligations (Current)	0.0	0.0	774K	157K	527.2K	672.6K	508.9K	0.0	3.2K	14.4K	16.6K	26.3K	26.3K	20.6K
Deferred Revenue	3.6M	5.3M	5.1M	0.0	6.7M	4.8M	3.2M	2.4M	2.1M	2.5M	2M	1.4M	791K	582.8K
Other Current Liabilities	7.8M	8.3M	0.0	6.7M	0.0	0.0	0.0	0.0	-850.9K	0.0	0.0	82K	0.0	0.0
Total Current Liabilities	14.3M	15.8M	17.9M	15.4M	15.6M	11.6M	9.3M	6.6M	7.2M	5.7M	5.1M	4.3M	4M	3.4M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	4.9M	4.9M	5.1M	4.2M	5M	4.2M	3.4M	0.0	21.8K
Other Non-Current Liabilities	263K	274K	283K	1.3M	450.2K	646.6K	338.1K	357.3K	384.5K	344.6K	171K	225.7K	0.0	0.0
Total Non-Current Liabilities	16.8M	17.4M	18.3M	17.3M	5.6M	6.9M	7M	5.4M	4.6M	5.3M	4.4M	3.7M	60.3K	56.8K
Capital Lease Obligations	16.5M	17.2M	18.7M	16.1M	5.7M	2M	2.3M	0.0	3.2K	17.5K	34.1K	60.3K	86.6K	55.6K
Total Liabilities	31M	33.2M	36.1M	32.7M	21.2M	18.6M	16.4M	12M	11.8M	11M	9.5M	7.9M	4M	3.4M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	45.3M	43.7M	32.3M	30.8M
Common Stock	1.1M	1.1M	1M	1M	1M	773.8K	574K	513.3K	509K	435.4K	19.5K	18.8K	700.0	700.0
Additional Paid-In Capital	431.9M	0.0	406.9M	390.8M	376.2M	127.7M	96.4M	82.3M	80.7M	56.4M	0.0	0.0	0.0	0.0
Retained Earnings	-261.5M	-216.9M	-175.8M	-137.9M	-114.3M	-95.2M	-83.4M	-70.5M	-61.6M	-51.7M	-48.4M	-45.4M	-33.9M	-31.4M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-19.5K	0.0	0.0	0.0
Other Total Stockholders' Equity	0.0	422M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	171.5M	206.3M	232.2M	254M	262.9M	33.2M	13.6M	12.3M	19.6M	5.1M	-3.1M	-1.6M	-1.5M	-590.7K
Total Equity	171.5M	206.3M	232.2M	254M	262.9M	33.2M	13.6M	12.3M	19.6M	5.1M	-3.1M	-1.6M	-1.5M	-590.7K
SUMMARY
Total Liabilities & Equity	202.5M	239.5M	268.3M	286.7M	284.1M	51.8M	30M	24.3M	31.4M	16.1M	6.4M	6.3M	2.5M	2.8M
Total Investments	135.5M	162.4M	164.7M	216.3M	207.3M	16M	1.5M	3.2M	0.0	0.0	0.0	0.0	0.0	0.0
Total Debt	17.9M	18M	18.7M	16.1M	5.7M	7M	7.2M	5.1M	5M	5M	5M	5M	1.9M	1.8M
Net Debt	-2.1M	-9.9M	-27.8M	5M	-42.1M	-11.8M	-8M	-6.2M	-20.3M	-6.7M	2.6M	1.6M	1.1M	417K
Shares Outstanding	106,606,648	106,606,648	106,606,648	106,606,648	106,606,648	106,606,648	106,606,648	106,606,648	106,606,648	106,606,648	106,606,648	106,606,648	106,606,648	106,606,648

SEC Filings

MXCT - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 29, 2026	June 17, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 27, 2026	March 23, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 25, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 24, 2026	March 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 20, 2026	March 16, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 13, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 12, 2025	November 12, 2025	2025	View Filing

Showing 1 to 10 of 78 filings

Related Guides

Blog Categories

Continue your MXCT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.